|
Launch of New Filler “Pleincell”
2017.02.15
|
|---|
|
In January 2017, Daehan New Pharm launched “Pleincell,” a hyaluronic acid (HA) filler containing lidocaine.
The name “Pleincell,” derived from the French word meaning “to be full,” represents the product’s ability to deliver natural volume. It features a patented cross-linking technology that creates a uniform HA particle structure, while its low residual BDDE content minimizes toxicity. Additionally, it is completely dissolvable with hyaluronidase, ensuring excellent safety and reversibility.
A filler is a medical device that restores skin tissue volume and improves wrinkles or facial contours through injection beneath the skin. A variety of fillers are currently available, including those based on HA, PLA, and PCA. The HA filler market alone has surpassed 100 billion KRW and continues to grow by more than 10% annually. Leveraging its strong brand recognition in wellness and beauty pharmaceuticals, Daehan New Pharm is actively reviewing the introduction of diverse facial aesthetic treatments and medical devices to expand its presence in this high-growth segment. |


Home